Feature | July 29, 2013| Edward J. Dougherty, senior healthcare advisor, Arent Fox LLC

Four Key Themes Emerging in the Medical Technology Market

Hospitals are changing the way they purchase new medical technologies

During the Med Tech Market Access conference in June, medical technology executives focused on challenges and opportunities when selling innovative medical technologies in the emerging U.S. and global healthcare marketplace. Organized by the legal firm Arent Fox LLP, participants discussed the “new normal” for the global medical device market where financial constraints increasingly impact both treatment and purchasing decision-making. As a result, companies develop products that demonstrate improved clinical outcomes and continue to provide services that raise the quality and efficiency of healthcare delivery in an increasingly resource-constrained environment.
 
During the meetings, device industry executives examined key sales strategies and critical pressure points in the global healthcare marketplace. As part of the talks, four key themes emerged that medical technology company executives should be aware of and that are outlined below:
 
1. A Holistic Approach: When deciding to purchase new medical technologies, hospitals increasingly will make decisions on a macro-level that are geared toward treating the broader population — not individual patients. Hospitals used to make purchasing decisions based almost exclusively on surgeon preference for specific patients. But now a more complex analysis is conducted to determine how a new technology will fit into treatment pathways for that patient population, what the demonstrated clinical value will be, and how the product will affect the cost of care.
 
2. The Reimbursement Squeeze: Reimbursement for hospital products and services is expected to continue to decline over the next five years. To survive, hospital executives are working to sustain managing with payment from all payers at a lower Medicare rate. As a result, costs are being cut at a time when the expense for treatment is increasing and the number of patients is expanding.
 
Compounding matters further: hospitals generally lose money when they treat Medicare patients, but they can make up for it through higher reimbursement from commercial health insurance plans. But over the next five years, it is expected that commercial payer reimbursement will decline even further. It is imperative for hospitals to develop profitable business models based on Medicare revenue levels.
 
3. A Longer Sales Cycle: Because customer budget constraints are lengthening the sales cycle, medtech manufacturers must work to develop a “value partnership.” Historically, there has been something of an adversarial relationship between manufacturers and provider customers. To bridge the gap, manufacturers are working to communicate more effectively and persuasively the value of their products and services. 
 
So far, the most successful strategy is built on collaboration between customers and manufacturers, where both parties see a value. For example, a manufacturer can develop a productive sales relationship that also meets the customer’s needs. This could include, for example, offering data from the manufacturer, discounted sales agreements based on the volume and longevity of the relationship, and cost savings for services.
 
4. Standardizing Innovation: While it may appear counter-intuitive, standardizing innovation can accelerate market adoption. Manufacturers and their customers must work together to develop and standardize a process for evaluating new technologies. That process will make it easier and faster to examine features and benefits of new products, including the clinical utility, economic impact, and how well it fits into clinical practice. The goal should be for the new technology to fit more seamlessly with existing treatment options already in use.
 
 
Editor’s note: Author Edward J. Dougherty is a senior healthcare advisor at Arent Fox LLC. The firm regularly advises clients on the development of reimbursement policy and provides counsel on strategies to ensure that their customers receive appropriate, value-based payment for their products and services. Its team of health law attorneys provides counsel and representation on all legal and regulatory aspects of large-scale transactions, regulatory compliance, investigations, and litigation. Dougherty can be contacted reached [email protected]
 

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Cardioband, valtech, Edwards Lifesciences, transcatheter mitral repair, transcatheter tricuspid valve repair, transcatheter annuloplasty

An illustration of how the transcatheter Cardioband System can used as a non-surgical form on annuloplasty repair. 

News | Heart Valve Technology| December 02, 2016
December 2, 2016 — Edwards Lifesciences Corp.
coronary CT angiography, CCTA, alcohol consumption, CAD, coronary artery disease, RSNA 2016
News | CT Angiography (CTA)| November 29, 2016
Researchers using coronary computed tomography angiography (CCTA) found no association between light to moderate...
Overlay Init